Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes ... funding from Wyeth/Pfizer, GSK, is a member of advisory ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch ... Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds ...

The Government-led immunization programs play a crucial role in increasing vaccine coverage and preventing infectious diseases globally. Many countries have implemented national vaccination ...

Colombian and Panama were also chosen by GSK as staging grounds for trials of the vaccine against the pneumococcal bacteria. Likewise, Marchese, explained the modus operandi: “Once a picked ...

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease ..

The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity ... launched Synflorix against pneumococcal diseases and acute otitis media caused by Streptococcus ...

Following the merger with Wyeth several years ago, Pfizer has a much stronger position in the vaccine industry with pneumococcal vaccine ... Pharmaceutical titan GSK looks undervalued as it ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...